argenex (NASDAQ:ARGX) Trading 6.3% Higher After Better-Than-Expected Earnings

argenex SE (NASDAQ:ARGX)’s stock price rose 6.3% during trading on Thursday following a better than expected earnings announcement. The stock traded as high as $904.98 and last traded at $905.12. 200,109 shares were traded during mid-day trading, a decline of 43% from the average daily volume of 351,695 shares. The stock had previously closed at $851.72.

The company reported $7.32 EPS for the quarter, beating analysts’ consensus estimates of $5.86 by $1.46. argenex had a return on equity of 44.37% and a net margin of 31.31%.The firm had revenue of $1.54 billion for the quarter, compared to analysts’ expectations of $1.45 billion.

argenex News Roundup

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported Q2 2026 EPS of $7.32, ahead of consensus at $5.86, and revenue of $1.54 billion versus expectations of $1.45 billion, reinforcing the view that execution remains strong. argenx earnings report and conference call
• Positive Sentiment: Global Vyvgart sales jumped sharply in the second quarter, with one report citing about 60% growth year over year, signaling accelerating demand for argenx’s lead product. Reuters article on Vyvgart sales jump
• Positive Sentiment: The company’s half-year 2026 results and business update point to continued commercial progress and a supportive backdrop as additional pipeline readouts approach. Half-year 2026 financial results and business update
• Positive Sentiment: Guggenheim reiterated a Buy rating, adding to the bullish sentiment around the stock after the earnings release. Guggenheim Buy rating article
• Neutral Sentiment: Investors are also focusing on the Q2 earnings call transcript and related coverage for more detail on management’s outlook, pipeline timing, and launch execution. Q2 2026 earnings call transcript

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ARGX shares. Wells Fargo & Company increased their target price on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research note on Monday, June 1st. Citigroup boosted their target price on shares of argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a research note on Tuesday. Morgan Stanley upped their price target on shares of argenex from $1,170.00 to $1,180.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Oppenheimer reduced their price target on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research note on Thursday, April 2nd. Finally, Bank of America raised their price target on shares of argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,042.67.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Oppenheimer & Co. Inc. raised its holdings in shares of argenex by 2.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock worth $372,000 after buying an additional 12 shares during the last quarter. Valeo Financial Advisors LLC lifted its stake in shares of argenex by 0.9% during the fourth quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock worth $1,153,000 after buying an additional 12 shares during the period. CI Investments Inc. grew its holdings in shares of argenex by 2.6% during the fourth quarter. CI Investments Inc. now owns 469 shares of the company’s stock valued at $394,000 after buying an additional 12 shares during the last quarter. Allworth Financial LP grew its holdings in shares of argenex by 12.7% during the fourth quarter. Allworth Financial LP now owns 115 shares of the company’s stock valued at $97,000 after buying an additional 13 shares during the last quarter. Finally, WPG Advisers LLC increased its position in shares of argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock valued at $63,000 after acquiring an additional 13 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenex Trading Up 8.6%

The firm has a 50-day moving average of $865.90 and a 200-day moving average of $814.39. The stock has a market capitalization of $57.84 billion, a price-to-earnings ratio of 41.17, a P/E/G ratio of 1.05 and a beta of 0.45.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.